Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Completed 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Gastrointestinal 1

Conditions

Carcinoma, Hepatocellular 79Carcinoma, Renal Cell 36Neoplasms 35Liver Neoplasms 22Carcinoma, Non-Small-Cell Lung 7Carcinoma 7Neoplasm Metastasis 6Melanoma 5Thyroid Neoplasms 4Kidney Neoplasms 4Breast Neoplasms 3Financial Stress 2Vaccinia 1Stomach Neoplasms 1Patient Preference 1Pancreatic Neoplasms 1Ovarian Neoplasms 1Neoplasms, Glandular and Epithelial 1Neoplasms by Site 1Neoplasms by Histologic Type 1Lymphoma 1Lung Neoplasms 1Liver Diseases 1Leukemia, Myelogenous, Chronic, BCR-ABL Positive 1Insulin-Like Growth Factor I, Resistance To 1Hypophosphatemia 1Hepatitis C 1Hepatitis B 1Glioblastoma 1Digestive System Neoplasms 1

Interventions

Cisplatin 3pembrolizumab 2bintrafusp alfa protein, human 2Gemcitabine 2vactosertib 1enzalutamide 1Trabedersen 1Temozolomide 1Sorafenib 1Radiotherapy, Intensity-Modulated 1Radiotherapy 1Paclitaxel 1Lomustine 1LY3300054 1LY-2157299 1Drug Delivery Systems 1Carboplatin 1Bevacizumab 1130-nm albumin-bound paclitaxel 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
INDUSTRY × Camurati-Engelmann Syndrome × Sorafenib × Clear all
NCT02178358 2022-02-25

A Study of LY2157299 in Participants With Advanced Hepatocellular Carcinoma

Eli Lilly and Company

Phase 2 Completed
132 enrolled 25 charts
Gastrointestinal

Camurati-Engelmann Syndrome, Carcinoma, Hepatocellular

Data powered by HemOnc (CC BY 4.0) Colophon âš¡